Abstract
Background Asthma is more common in females and more common in night shift workers. Since increasing numbers of females are becoming shift workers it is important to determine if shift work-associated asthma risk is higher in females.
Research Question Is increasing frequency of night shift work more strongly related to prevalent asthma in females than in males?
Study Design and Methods We used cross-sectional data from >280,000 UK Biobank participants and logistic regression models adjusted for demographic and lifestyle factors to describe sex differences in prevalent asthma related to shift work frequency. To obtain mechanistic insights, we explored associations with chronotype, sex hormones and menopause.
Results Compared to female day workers, female permanent night shift workers had higher covariate-adjusted odds of moderate-severe asthma (OR: 1.50 (95% CI 1.18 – 1.91)) but there was no corresponding relationship in males (OR 0.95 (95% CI 0.72 – 1.26); sex interaction p-value = 0.01). Similar relationships were observed for ‘all asthma’ and for ‘wheeze or whistling in the chest’ outcomes. Female shift work-related asthma was driven by relationships in postmenopausal women not using HRT (e.g., adjusted OR: 1.89 (1.24-2.87) for moderate-severe asthma; sex interaction p-value = 0.02 in permanent nightshift workers compared to dayworkers) but these relationships attenuated to the null in postmenopausal women using HRT.
Interpretation Our finding that increasing shift work frequency is more strongly related to asthma in females than in males could have Public Health implications. Intervention studies should determine if modifying shift work schedules or HRT can reduce asthma risk in females.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Asthma and Lung UK WAPG22/100005. RJM is supported by the Asthma and Lung UK grant above. DWR is supported by MRC grants MR/W019000/1, MR/V034049/1 and the NIHR Oxford Health Biomedical Research Centre grant NIHR203316. The views expressed in the manuscript are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. JL is working as an Oxford - Novo Nordisk fellow funded by Novo Nordisk. JB is supported by research grant MR/X011372/1. He is also a part time employee of Novo Nordisk Research Centre, Oxford. HJD holds a MRC Clinician Scientist Fellowship MRC-CSF-MR/V029460/1 and is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. All UKB participants provided consent, including permission for their health to be followed-up through linkage to health-related records. This study was approved by UKB under application number 6818
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of Interest RJM, DWR, JL and HJD report no conflicts of interest. JB is a part time employee of Novo Nordisk Research Centre Oxford, limited. MKR reports receiving consultancy fees from Eli Lilly and has modest stock holding in GSK unrelated to the submitted work.
Funding This work was funded by Asthma and Lung UK WAPG22/100005.
RJM is supported by the Asthma and Lung UK grant above.
DWR is supported by MRC grants MR/W019000/1, MR/V034049/1 and the NIHR Oxford Health Biomedical Research Centre grant NIHR203316. The views expressed in the manuscript are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
JL is working as an Oxford - Novo Nordisk fellow funded by Novo Nordisk.
JB is supported by research grant MR/X011372/1. He is also a part time employee of Novo Nordisk Research Centre, Oxford.
HJD holds a MRC Clinician Scientist Fellowship MRC-CSF-MR/V029460/1 and is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308).
Data Availability
All data is available after request from the UK Biobank
Abbreviations
- BMI
- Body Mass Index
- CI
- Confidence Interval
- FEV1
- Forced Expiratory Volume in 1 second
- HRT
- Hormone Replacement Therapy
- OCP
- Oral Contraceptive Pill
- OR
- Odds Ratio
- RCT
- Randomized Controlled Trial
- SHBG
- Sex Hormone Binding Globulin
- TDI
- Townsend Deprivation Index.
